



## Exploring Drug Resistance and Biofilm Formation in Gram-Negative Clinical Isolates

**Priyanka Mane**(Assistant Professor)<sup>1</sup>, **S R Patil** (Professor and Head)<sup>1</sup>, **R V Shinde** (Associate Professor)<sup>1</sup>, **S K Pawar** (Associate Professor)<sup>1</sup> and **H V Patil** (Associate Professor)<sup>1</sup>

<sup>1</sup>Department of Microbiology, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth (Deemed to be university), Karad, Maharashtra, India.

Corresponding author: S R Patil (Professor and Head)

Department of Microbiology, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth (Deemed to be university), Karad, Maharashtra, India.

(Received: 05 August 2023

Revised: 12 September

Accepted: 07 October)

### KEYWORDS

multidrug-resistant  
bacteria,  
Citrobacter species.

### ABSTRACT:

Background: Biofilms are clusters of microorganisms surrounded by a slimy matrix composed of extracellular polysaccharides known as polysaccharide intercellular adhesion (PIA). Bacterial species frequently associated with biofilm formation include *Enterococcus faecalis*, *Staphylococcus aureus*, *Escherichia coli*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa* [1], [3]. This study was conducted to analyze the antibiotic resistance patterns and assess the capacity to create biofilms in clinical isolates of gram-negative bacteria. Methods: All clinical samples received in the laboratory for microbial culture during a one-year study period were incorporated into this research. We conducted antibiotic susceptibility testing, detected extended-spectrum beta-lactamase (ESBL) and metallo-beta-lactamase (MBL) presence in clinical isolates. Biofilm production was assessed using the Congo red agar method, Christenson's Test Tube method, and the Tissue culture plate method. Results: A total of 320 gram-negative isolates were identified in this study. The highest proportion consisted of *Klebsiella pneumoniae* (32.62%), followed by *Escherichia coli* (28.54%), *Acinetobacter baumannii* (16.41%), *Pseudomonas aeruginosa* (16.61%), and *Citrobacter* species (3.67%). The majority of the isolates exhibited resistance to ampicillin (93.47%), amoxiclavate (86.46%), and ceftazidime (75%). Conclusion: There is a rising prevalence of multidrug-resistant bacteria that also form biofilms [4]. It is advisable to implement regular monitoring of multidrug resistance patterns and biofilm formation in clinical laboratories to provide guidance for appropriate antibiotic treatment.

## I. INTRODUCTION

Biofilms consist of clusters of microorganisms enclosed within a matrix of extracellular polysaccharide, known as polysaccharide intercellular adhesion (PIA). They have been linked to various chronic and persistent infections. Biofilm formation represents an adaptive and protective growth strategy that allows bacteria to survive in hostile environments, such as the human host [5]. This growth mode also facilitates their dispersal and colonization of new habitats, guided by chemical communication through quorum sensing. In many instances, chronic infections are accompanied by the development of biofilms. Over the past decade,

there has been a noticeable increase in bacteria acquiring the ability to form biofilms as a means of survival in challenging environments where mechanical stress, desiccation, and exposure to biocides are prevalent threats. Bacteria capable of forming biofilms are frequently responsible for numerous nosocomial infections. According to several reports, more than 60% of infections acquired in hospitals are caused by organisms capable of producing biofilms. Biofilms are linked to various medical conditions, such as indwelling medical devices, catheters, urinary tract infections, dental plaque, upper respiratory tract infections, peritonitis, and urogenital infections. They



often lead to chronic and persistent infections that are difficult to treat effectively. Both Gram-positive and Gram-negative bacteria possess the ability to create biofilms. Common bacterial species involved in this process include *Enterococcus faecalis*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Streptococcus viridans*, *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus mirabilis*, and *Pseudomonas aeruginosa*. Among these, *Pseudomonas aeruginosa* and *Staphylococcus aureus* are notable bacterial pathogens that have developed intricate mechanisms for evasion, counter-inhibition, and subjugation in their competition for space and nutrients. Organisms capable of producing biofilms exhibit significantly higher antibiotic resistance compared to their planktonic counterparts, with resistance levels potentially increasing by up to a thousandfold [6]. This resistance primarily arises from the inability of antibiotics to penetrate the protective polysaccharide matrix that surrounds biofilms. Within the host, this matrix shields biofilm bacteria from innate immune defenses, such as opsonization and phagocytosis, as well as from antibiotic treatments [7]. It is widely recognized that biofilms pose considerable challenges in terms of eradication and often display resistance to systemic antibiotic therapies. In such cases, the removal of infected medical devices may become necessary. The present study aimed to identify antibiotic resistance patterns and assess the biofilm-forming ability of gram-negative clinical isolates.

## II. MATERIALS AND METHODS

This study is a prospective investigation conducted within a hospital setting, and it received approval from the Institutional Ethical Committee. During a one-year study period, we collected various clinical samples such as urine, pus, blood, sputum, and swabs (including wound, throat, vaginal, tracheal, endotracheal, or any device-related swabs) for microbial culture analysis. Every sample collection adhered strictly to established protocols and maintained stringent aseptic precautions. These samples underwent processing using standardized procedures for the isolation and identification of pathogens. Antibiotic susceptibility testing was conducted using the Kirby-Bauer disc diffusion method on Muller Hilton Agar [8]. The isolated organisms were categorized into multidrug-resistant

(MDR) organisms based on their resistance profiles to various antibiotics. Additionally, we performed the detection of extended-spectrum beta-lactamases (ESBL) and metallo-beta-lactamases (MBL) in clinical isolates. For the phenotypic detection of ESBL, we followed the Clinical and Laboratory Standards Institute (CLSI) confirmatory method. Initially, ESBL production was assessed using Ceftazidime (30  $\mu$ g) and Cefotaxime (30  $\mu$ g) discs both individually and in combination with Clavulanic acid (10  $\mu$ g) [9]. Interpretation: A positive result for extended-spectrum beta-lactamase (ESBL) production is indicated when there is a 5 mm or greater increase in the zone diameter for ceftazidime or cefotaxime when tested in combination with clavulanic acid compared to their respective zones when tested alone. This increase suggests that the presence of clavulanic acid has effectively inhibited the ESBL activity, resulting in a larger zone of inhibition [10]. To detect metallo-beta-lactamases (MBL), various methods were employed, including the Imipenem-EDTA combined disc test, the Double disc synergy test using Imipenem and EDTA, and the EDTA disc potentiation using ceftazidime and cefepime. These techniques rely on the capacity of metal chelators like EDTA and thiol-based compounds to inhibit MBL activity. In the case of the phenotypic Imipenem-EDTA combined disc test (IMP EDTA CDT), the test organism is first inoculated on a Mueller-Hinton Agar (MHA) plate. Subsequently, two discs are placed on the MHA plate: one containing 10  $\mu$ g of imipenem and the other being an imipenem-EDTA combined disc with 10  $\mu$ g of imipenem and 720  $\mu$ g of EDTA. A positive result for MBL is confirmed when there is a significant increase of more than 7 mm in the inhibition zone surrounding the imipenem-EDTA disc in comparison to the zone around the imipenem disc alone. This method effectively identifies MBL-producing strains based on their susceptibility to imipenem in the presence of EDTA, which inhibits MBL activity. Biofilm production was evaluated through the utilization of three distinct methods: the Congo red agar method, Christenson's Test Tube method, and the Tissue culture plate method. These diverse approaches collectively facilitated a thorough assessment of biofilm formation, each contributing valuable insights into the adhesive properties and biofilm-forming capacities of the microorganisms under investigation [11].



• **Congo red method:** In the Congo red agar method, colonies were inoculated onto agar plates and then incubated at 36 degrees Celsius for a duration of 24 hours. Colonies that exhibited a black coloration and possessed a dry, metallic consistency were identified as positive indicators of slime production.

• **Test tube method:** colonies were inoculated into Brain Heart Infusion broth enriched with 1% sucrose. Following an overnight incubation period at 36 degrees Celsius, the tubes were carefully decanted, washed three times with phosphate-buffered saline, and subsequently stained with 0.2% crystal violet. The presence of a discernible violet film adhering to the inner walls and bottom of the tube was regarded as a positive indication of biofilm formation.

• **Tissue Culture Plate Method:** colonies obtained from fresh agar plates were first inoculated in a culture medium (Brain Heart Infusion broth with 1% sucrose) and incubated for 16 hours at 36°C. This culture was then diluted at a ratio of 1:100 using fresh medium. Next, 200 µl of this diluted broth was added to each well of a 96-well microtiter plate. The tissue culture plates were incubated for 16 and 24 hours at 36°C.

Figure 1 presents the demographic profile of the samples in our study. The highest proportion of microorganisms was isolated from blood cultures, accounting for 28.35% of the total, followed closely by samples obtained from medical devices at 28.29%, and urine samples at 23.65%. The majority of the samples were collected from patients admitted to the hospital (90.42%), residing in rural areas (75.02%), and were from female patients (63.10%). Regarding age distribution, the largest proportion of samples came from

Following incubation, the contents of each well were gently removed by tapping the plates, and the wells were washed four times with 0.2 mL of phosphate-buffered saline (PBS, pH 7.2) to eliminate any free-floating 'planktonic' bacteria. The biofilms formed by adherent 'sessile' organisms in the plates were then fixed using sodium acetate (2%) and stained with crystal violet (0.1% w/v). The plates were allowed to dry, and the optical density (OD) of the stained adherent bacteria was measured using a micro ELISA auto reader (Thermo LabSystems) at a wavelength of 450 nm (OD 450 nm). These OD values served as an index for quantifying bacteria adhering to surfaces and forming biofilms.

### III. RESULTS

Throughout the study period, a total of 4,600 distinct clinical samples were received in the laboratory for aerobic bacterial culture and subsequent sensitivity testing. Among these, 320 non-repetitive gram-negative bacteria were selected and included in the study for further analysis and investigation.

individuals aged over 19 years, making up 37.17% of the total, followed by the age group under 1 month, representing 30.50%. Out of the 320 gram-negative bacterial (GNB) isolates included in the study, the most prevalent was *Klebsiella pneumoniae*, accounting for 32.62% of the total isolates, followed by *Escherichia coli* at 28.54%<sup>11</sup>. Other significant GNB isolates included *Acinetobacter baumannii* (16.41%), *Pseudomonas aeruginosa* (16.61%), and *Citrobacter* species (3.67%)




FIG 1: Showing demographic profile of samples




FIGURE 2: Distribution of Gram negative bacterial isolates

The antibiotic resistance patterns observed among the gram-negative bacterial (GNB) isolates. The majority of these isolates demonstrated high resistance rates, with the maximum resistance observed against ampicillin (93.07%), followed closely by amoxiclav (87.26%), ceftazidime (72%), and ciprofloxacin (73.25%). On the other hand, these GNB isolates exhibited sensitivity to meropenem (70.34%), piperacillin-tazobactam (66.20%), and cefepime (57.05%) [13], [14]. It is noteworthy that *Klebsiella pneumoniae*, *Acinetobacter baumannii*, and *Pseudomonas aeruginosa* were identified as multi-drug resistant, indicating their resistance to multiple classes of antibiotics, which is a concerning trend in healthcare settings.

#### IV. DISCUSSION

In our current study, we identified a total of 320 gram-negative bacterial (GNB) isolates, with a notable predominance of *Klebsiella pneumoniae* and *Escherichia coli*. Interestingly, previous studies conducted by Dumar et al. and Fatima et al [15], have also reported *Escherichia coli* as the predominant bacterial isolate. It's worth noting that variations in bacterial prevalence across studies may be attributed to differences in geographical locations and the types of populations under investigation. Furthermore, our study revealed that the highest number of positive isolates were detected in blood cultures, accounting for 29.35% of the total, which aligns with observations made in studies conducted by Khan et al. and Roy et al [16]. These findings suggest a consistent trend in the prevalence of gram-negative bacterial isolates in blood cultures across different research efforts. In our present study, we observed that *Klebsiella pneumoniae* was predominantly

isolated from blood cultures, representing 40.66% of the total isolates. These findings are in agreement with several other studies conducted by Negussie A et al., Jyoti et al., Vanitha RN et al. [17], and Nidhi Pal et al. [18], which also reported *Klebsiella pneumoniae* as a major isolate from blood samples. This concordance in results suggests a consistent trend in the prevalence of *Klebsiella pneumoniae* in blood cultures across multiple research studies. Similarly, in our study, *Escherichia coli* was found to be the predominant isolate in urine samples, accounting for 80.66% of the isolates. This finding is consistent with the observations made by Alanazi MQ et al. and Isaac Odongo et al., who also reported a high prevalence of *Escherichia coli* in urine samples in their respective studies. These consistent findings indicate that *Escherichia coli* is frequently associated with urinary tract infections across different research studies [19]. In our present study, the highest proportion of biofilm producers was observed among isolates obtained from medical devices, accounting for 25.67% of the total, closely followed by blood samples at 23.25%. Conversely, the lowest occurrence of biofilm producers was noted in urine samples (80.06%) and other sample types (82.33%). Among the 327 gram-negative bacterial (GNB) isolates tested, biofilm production was identified in 64 isolates (19.87%) using the Tissue Culture Plate (TCP) method, 38 isolates (11.62%) through the Congo Red Agar (CRA) method, and 23 isolates (7.03%) via the Tube method. These findings align with the results of a study conducted by Pragyan et al. [20], where they reported similar trends. In their study, out of 200 isolates, 45.6% produced biofilm using the TCP method, 39.3% were detected as biofilm producers by the Tube adherence method, and



11% showed biofilm production using the Congo Red Agar method. Importantly, the Tissue Culture Plate (TCP) method was found to be the most sensitive in detecting biofilm production, followed by the Tube method (TM) and Congo Red Agar method (CRA), which is in agreement with the observations in our study. Indeed, *Pseudomonas aeruginosa* is notorious in healthcare settings as a hospital-acquired, drug-resistant pathogen. It is well-known for its propensity to cause chronic infections, largely due to its ability to form robust biofilms. These biofilms make *Pseudomonas aeruginosa* particularly challenging to eradicate and contribute to its resistance against various antibiotics [21]. Similarly, *Acinetobacter baumannii* has emerged as a troublesome pathogen, especially in intensive care units (ICUs). In recent years, it has gained notoriety as a hospital superbug due to its propensity to develop multidrug-resistant (MDR) and pandrug-resistant (PDR) profiles. *Acinetobacter baumannii* possesses a remarkable capacity to acquire resistance determinant genes, including those encoding enzymes like extended-spectrum beta-lactamases (ESBL) and metallo-beta-lactamases (MBL) [22]. This ability to acquire such resistance determinants makes it exceptionally resistant to most higher-order antibiotics, posing a significant challenge to infection control and treatment efforts in healthcare settings.

## V. CONCLUSION

The rising prevalence of multidrug-resistant and biofilm-forming organisms presents a concerning glimpse into the emergence of hospital superbugs in our current era. To effectively address this growing threat, it is imperative to recommend routine monitoring of multidrug resistance patterns and biofilm detection in clinical laboratories. Additionally, strict adherence to institutional antibiotic policies, coupled with the proper implementation and continuous monitoring of hospital infection control and prevention activities, is essential [23], [24]. These measures are critical for containing the spread of superbugs, safeguarding patient health, and preserving the effectiveness of antibiotics in healthcare settings.

## FUNDING

This research did not receive any specific grant from funding agencies in the public, commercial, or nonprofit

sectors.

## CONFLICTS OF INTEREST

The authors declared no conflict of interest.

## AUTHORS' CONTRIBUTIONS

All authors equally contributed to preparing this article.

## References

- [1] Mathur T, Singhal S, Khan S, Upadhyay DJ, Fatma T, Rattan
- [2] Detection of biofilm formation among the clinical isolates of Staphylococci: an evaluation of three different screening methods. *Indian J Med Microbiol.* 2006;24(1):25-9.
- [3] Dardi CK. Biofilm formation and antimicrobial resistance pattern among uropathogens. *Int J Med Res Health Sci.* 2015;4(2):339-44.
- [4] Lewis K. Riddle of biofilm resistance. *Antimicrob Agents Chemother.* 2001;45(4):999-1007.
- [5] Donlan RM, Murga R, Bell M. Protocol for detection of biofilms on needleless connectors attached to central venous catheters. *J Clin Microbiol.* 2001;39(2):750-3.
- [6] Soto SM, Smithson A, Horcajada JP, Martinez JA, Mensa JP, Vila J. Implication of biofilm formation in the persistence of urinary tract infection caused by uropathogenic *Escherichia coli*. *Clin Microbiol Infect.* 2006;12(10):1034-6.
- [7] Ruhul R, Kataria R. Biofilm patterns in gram-positive and gram-negative bacteria. *Microbiol Res.* 2021;251:126829
- [8] Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. *Clin Microbiol Rev.* 2002;15(2):167-93.
- [9] Collee. Mackie & McCartney Practical Medical Microbiology. 14th ed. Elsevier; 1996. Freeman DJ, Falkiner FR, Keane CT. New method for detecting slime production by coagulase negative staphylococci. *J Clin Pathol.* 1989;42(8):872-4.
- [10] CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 27th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.
- [11] Panchal CA, Oza SS, Mehta SJ. Comparison of four phenotypic methods for detection of metallo- $\beta$ -lactamase-producing Gram-negative





- bacteria in rural teaching hospital. *J Lab Physicians*. 2017;9(2):81-3.
- [12] Christensen GD, Simpson WA, Bisno AL, Beachey EH. Adherence of slime-producing strains of *Staphylococcus epidermidis* to smooth surfaces. *Infect Immun*. 1982;37(1):318-26.
- [13] Dumar R, Baral R, Shrestha LB. Study of biofilm formation and antibiotic resistance pattern of gram-negative Bacilli among the clinical isolates at BPKIHS, Dharan. *BMC Res Notes*. 2019;12:38.
- [14] Fatima S, Prasanthi K, Nagamani K. Comparative evaluation of biofilm production in Multidrug resistant and sensitive Gram negative clinical isolates. *Int J Curr Microbiol Appl Sci*. 2015;4(6):918-26.
- [15] Khanal B, Harish BN, Sethuraman KR, Srinivasan S. Infective endocarditis: report of a prospective study in an Indian hospital. *Trop Doct*. 2002;32(2):83-5.
- [16] Roy I, Jain A, Kumar M, Agarwal SK. Bacteriology of neonatal septicemia in a tertiary care hospital of northern India. *Indian J Med Microbiol*. 2002;20(3):156-9.
- [17] Negussie A, Mulugeta G, Bedru A, Ali I, Shimeles D, Lema T, et al. Bacteriological Profile and Antimicrobial Susceptibility Pattern of Blood Culture Isolates among Septicemia Suspected Children in Selected Hospitals Addis Ababa, Ethiopia. *Int J Biol Med Res*. 2015;6(1):4709-17.
- [18] Sonawane JP, Kamath N, Shetty K, Swaminathan R. Bacteriological Profile and Antimicrobial Susceptibility of Blood Culture Isolates from Tertiary Care Hospital, Navi Mumbai. *Springerplus*. 2015;4:314.
- [19] Alanazi MQ, Alqahtani FY, Aleanizy FS. An evaluation of *E. coli* in urinary tract infection in emergency department at KAMC in Riyadh, Saudi Arabia: retrospective study. *Ann Clin Microbiol Antimicrob*. 2018;17(1):3.
- [20] Odongo I, Ssemambo R, Kungu JM. Prevalence of *Escherichia Coli* and Its Antimicrobial Susceptibility Profiles among Patients with UTI at Mulago Hospital. *Interdiscip Perspect Infect Dis*. 2020;2020:8042540.
- [21] Sidhu S, Arora U, Devi P. Prevalence of Nonfermentative Gram Negative Bacilli In Seriously ill Patients With Bacteraemia. *JK Sci*. 2010;12(4):168-71.
- [22] Rattanaumpawan P, Ussavasodhi P, Kiratisin P, Aswapokee N. Epidemiology of bacteremia caused by uncommon non-fermentative gram-negative bacteria. *BMC Infect Dis*. 2013;13:167.
- [23] Juyal D, Prakash R, Shanakarnarayan SA, Sharma M, Negi V, Sharma N. Prevalence of non-fermenting gram negative bacilli and their in vitro susceptibility pattern in a tertiary care hospital of Uttarakhand: A study from foothills of Himalayas. *Saudi J Health Sci*. 2013;2(2):108-12.
- [24] Mshana SE, Kamugisha E, Mirambo M, Chakraborty T, Lyamuya EF. Prevalence of multiresistant gram-negative organisms in a tertiary hospital in Mwanza. *BioMed Cent*. 2009;2:49. doi:10.1186/1756-0500-2-49.